Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other May 09 | 2024Novo Partners with Metaphore for Next-Gen Obesity Assets; Altimmune, Xeris, MannKind, and Viatris Q1 ’24 EarningsPurchase Blast
$599
Posted in: Other May 08 | 2024BI Partners with Walgreens for Clinical Trial Enrollment; Cytokinetics Initiates Pediatric Aficamten oHCM StudyPurchase Blast
$599
Posted in: Other May 07 | 2024Madrigal, Vertex, Ionis, Esperion, and Scholar Rock Q1 ‘24 Earnings; Tandem t:connect App RecalledPurchase Blast
$599
Posted in: Glucagon, Other May 06 | 2024Xeris Exclusively Partners with Beta Bionics; Eccogene IPO in 2025?Purchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other, SGLT2i May 03 | 2024Novo London, Tandem, and Lexicon Q1 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other May 02 | 2024Amgen, Regeneron, and Alnylam Q1 ’24 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other May 02 | 2024Novo to Face Two FDA Adcoms in 2024; Novo Q1 ‘24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other May 01 | 2024FTC Investigating Diabetes and Obesity Orange Book Patent Listings; Pfizer and Amarin Q1 ’24 Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Apr 30 | 2024Eversense CGM Receives iCGM DesignationPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Apr 30 | 2024Lilly Raises 2024 Guidance on Strong Mounjaro/Zepbound Performance; Lilly Q1 ’24 Earnings UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Apr 29 | 2024Lilly Initiates Retatrutide CV and Renal Outcomes Study; Novo Initiates New Ph3 Cagrisema Maintenance Dose Study; US Senate Investigates Ozempic/Wegovy Pricing; Teladoc Q1 ’24 Earnings; Vance Swanson Joins Beta BionicsPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Other Apr 25 | 2024Dexcom Q1 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Apr 25 | 2024Viking, AZ, Sanofi, and Merck Q1 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Apr 24 | 2024Study on Eligible Wegovy Patients through Medicare; Roche Q1 ’24 EarningsPurchase Blast
$599
Posted in: Other, SGLT2i Apr 23 | 2024Novartis Q1 ’24 Earnings; Vertex Partners with TreeFrog for T1DM ManufacturingPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Other Apr 22 | 2024SELECT up for CHMP Opinion?; April CHMP Agenda; BI Partners for MASH; Lilly Acquires Nexus Manufacturing SitePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Apr 18 | 2024Metsera Launches as Obesity Company; Lilly Initiates Ph2 Tizepatide+Mibavademab Obesity Trial; Skye Uplists to Nasdaq Global MarketPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Apr 17 | 2024SURMOUNT-OSA Topline Results; Abbott Q1 ‘24 Earnings; Lilly Insulin Settlement Dropped; NeuroBo Doses First Patient in Ph1 Obesity TrialPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
